Upon regulatory success in EU and US assuming a 5 per 100k incidence of IIH at 50% market penetration and 10 per 100k prevalence of IIH at 20% market penetration I had done some numbers at a peak sales multiple of 3x that this would be worth about 2.5bil. Obviously a long way from there and I doubt it will make it that far but I don't see anything south of 500m as a reasonable buyout assuming regulatory approval in EU. Just a forecast, anyway.
Upon regulatory success in EU and US assuming a 5 per 100k...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
